<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/">
<channel>
<title>心血管高分期刊</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;ff=20240607180913&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;utm_source=Chrome
    <description>心血管高分期刊: Latest results from PubMed</description>
<atom:link href="https://pubmed.ncbi.nlm.nih.gov/rss-feed/?feed_id=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;utm_medium=rss&amp;ff=20240607180913&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;v=2.18.0.post9+e462414&amp;utm_campaign=pubmed-2&amp;fc=20230708114047&amp;utm_source=Chrome" rel="self"></atom:link>
<docs>http://www.rssboard.org/rss-specification</docs>
<generator>PubMed RSS feeds (2.18.0.post9+e462414)</generator>
<language>en</language>
<lastbuilddate>Fri, 07 Jun 2024 22:09:14 +0000</lastbuilddate>
<pubDate>Fri, 07 Jun 2024 06:00:00 -0400</pubDate>
<ttl>120</ttl>
<item>
<title>Atrial fibrillation and long-term cardiovascular outcomes: bringing the whole picture into focus</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38848112/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240607180913&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 7:ehae347. doi: 10.1093/eurheartj/ehae347. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38848112/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240607180913&v=2.18.0.post9+e462414">38848112</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae347>10.1093/eurheartj/ehae347</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38848112</guid>
<pubDate>Fri, 07 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Benjamin A Steinberg</dc:creator>
<dc:date>2024-06-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Atrial fibrillation and long-term cardiovascular outcomes: bringing the whole picture into focus</dc:title>
<dc:identifier>pmid:38848112</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae347</dc:identifier>
</item>
<item>
<title>Improving clinical outcomes for patients with coronary artery disease despite no standard modifiable cardiovascular risk factors (SMuRF): not out of the woods yet</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38848109/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240607180913&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 7:ehae271. doi: 10.1093/eurheartj/ehae271. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38848109/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240607180913&v=2.18.0.post9+e462414">38848109</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae271>10.1093/eurheartj/ehae271</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38848109</guid>
<pubDate>Fri, 07 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Gemma A Figtree</dc:creator>
<dc:creator>Michael P Gray</dc:creator>
<dc:date>2024-06-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Improving clinical outcomes for patients with coronary artery disease despite no standard modifiable cardiovascular risk factors (SMuRF): not out of the woods yet</dc:title>
<dc:identifier>pmid:38848109</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae271</dc:identifier>
</item>
<item>
<title>Non-ST-elevation acute coronary syndromes with previous coronary artery bypass grafting: is a routine invasive strategy needed?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38848108/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240607180913&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 7:ehae287. doi: 10.1093/eurheartj/ehae287. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38848108/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240607180913&v=2.18.0.post9+e462414">38848108</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae287>10.1093/eurheartj/ehae287</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38848108</guid>
<pubDate>Fri, 07 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Frans J Beerkens</dc:creator>
<dc:creator>Deepak L Bhatt</dc:creator>
<dc:date>2024-06-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Non-ST-elevation acute coronary syndromes with previous coronary artery bypass grafting: is a routine invasive strategy needed?</dc:title>
<dc:identifier>pmid:38848108</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae287</dc:identifier>
</item>
<item>
<title>Polygenic risk score adds to a clinical risk score in the prediction of cardiovascular disease in a clinical setting</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38848106/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240607180913&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: In a clinical setting, the addition of genetic information to clinical risk assessment significantly improved the identification of individuals who went on to have a major CVD event as being at high risk, especially among younger individuals. The findings provide important real-world evidence of the potential value of implementing a CVD-PRS into health systems.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 7:ehae342. doi: 10.1093/eurheartj/ehae342. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: A cardiovascular disease polygenic risk score (CVD-PRS) can stratify individuals into different categories of cardiovascular risk, but whether the addition of a CVD-PRS to clinical risk scores improves the identification of individuals at increased risk in a real-world clinical setting is unknown.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: The Genetics and the Vascular Health Check Study (GENVASC) was embedded within the UK National Health Service Health Check (NHSHC) programme which invites individuals between 40-74 years of age without known CVD to attend an assessment in a UK general practice where CVD risk factors are measured and a CVD risk score (QRISK2) is calculated. Between 2012-2020, 44,141 individuals (55.7% females, 15.8% non-white) who attended an NHSHC in 147 participating practices across two counties in England were recruited and followed. When 195 individuals (cases) had suffered a major CVD event (CVD death, myocardial infarction or acute coronary syndrome, coronary revascularisation, stroke), 396 propensity-matched controls with a similar risk profile were identified, and a nested case-control genetic study undertaken to see if the addition of a CVD-PRS to QRISK2 in the form of an integrated risk tool (IRT) combined with QRISK2 would have identified more individuals at the time of their NHSHC as at high risk (QRISK2 10-year CVD risk of ≥10%), compared with QRISK2 alone.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: The distribution of the standardised CVD-PRS was significantly different in cases compared with controls (cases mean score .32; controls, -.18, P = 8.28×10-9). QRISK2 identified 61.5% (95% confidence interval [CI]: 54.3%-68.4%) of individuals who subsequently developed a major CVD event as being at high risk at their NHSHC, while the combination of QRISK2 and IRT identified 68.7% (95% CI: 61.7%-75.2%), a relative increase of 11.7% (P = 1×10-4). The odds ratio (OR) of being up-classified was 2.41 (95% CI: 1.03-5.64, P = .031) for cases compared with controls. In individuals aged 40-54 years, QRISK2 identified 26.0% (95% CI: 16.5%-37.6%) of those who developed a major CVD event, while the combination of QRISK2 and IRT identified 38.4% (95% CI: 27.2%-50.5%), indicating a stronger relative increase of 47.7% in the younger age group (P = .001). The combination of QRISK2 and IRT increased the proportion of additional cases identified similarly in women as in men, and in non-white ethnicities compared with white ethnicity. The findings were similar when the CVD-PRS was added to the atherosclerotic cardiovascular disease pooled cohort equations (ASCVD-PCE) or SCORE2 clinical scores.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: In a clinical setting, the addition of genetic information to clinical risk assessment significantly improved the identification of individuals who went on to have a major CVD event as being at high risk, especially among younger individuals. The findings provide important real-world evidence of the potential value of implementing a CVD-PRS into health systems.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38848106/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240607180913&v=2.18.0.post9+e462414">38848106</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae342>10.1093/eurheartj/ehae342</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38848106</guid>
<pubDate>Fri, 07 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Nilesh J Samani</dc:creator>
<dc:creator>Emma Beeston</dc:creator>
<dc:creator>Chris Greengrass</dc:creator>
<dc:creator>Fernando Riveros-McKay</dc:creator>
<dc:creator>Radoslaw Debiec</dc:creator>
<dc:creator>Daniel Lawday</dc:creator>
<dc:creator>Qingning Wang</dc:creator>
<dc:creator>Charley A Budgeon</dc:creator>
<dc:creator>Peter S Braund</dc:creator>
<dc:creator>Richard Bramley</dc:creator>
<dc:creator>Shireen Kharodia</dc:creator>
<dc:creator>Michelle Newton</dc:creator>
<dc:creator>Andrea Marshall</dc:creator>
<dc:creator>Andre Krzeminski</dc:creator>
<dc:creator>Azhar Zafar</dc:creator>
<dc:creator>Anuj Chahal</dc:creator>
<dc:creator>Amadeeep Heer</dc:creator>
<dc:creator>Kamlesh Khunti</dc:creator>
<dc:creator>Nitin Joshi</dc:creator>
<dc:creator>Mayur Lakhani</dc:creator>
<dc:creator>Azhar Farooqi</dc:creator>
<dc:creator>Vincent Plagnol</dc:creator>
<dc:creator>Peter Donnelly</dc:creator>
<dc:creator>Michael E Weale</dc:creator>
<dc:creator>Christopher P Nelson</dc:creator>
<dc:date>2024-06-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Polygenic risk score adds to a clinical risk score in the prediction of cardiovascular disease in a clinical setting</dc:title>
<dc:identifier>pmid:38848106</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae342</dc:identifier>
</item>
<item>
<title>Fractional flow reserve or optical coherence tomography for angiographically intermediate coronary stenoses: 5-year outcomes in the FORZA trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38848104/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240607180913&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 7:ehae290. doi: 10.1093/eurheartj/ehae290. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38848104/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240607180913&v=2.18.0.post9+e462414">38848104</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae290>10.1093/eurheartj/ehae290</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38848104</guid>
<pubDate>Fri, 07 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Francesco Burzotta</dc:creator>
<dc:creator>Andrea Zito</dc:creator>
<dc:creator>Cristina Aurigemma</dc:creator>
<dc:creator>Enrico Romagnoli</dc:creator>
<dc:creator>Francesco Bianchini</dc:creator>
<dc:creator>Emiliano Bianchini</dc:creator>
<dc:creator>Lazzaro Paraggio</dc:creator>
<dc:creator>Carolina Ierardi</dc:creator>
<dc:creator>Filippo Crea</dc:creator>
<dc:creator>Antonio Maria Leone</dc:creator>
<dc:creator>Carlo Trani</dc:creator>
<dc:date>2024-06-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Fractional flow reserve or optical coherence tomography for angiographically intermediate coronary stenoses: 5-year outcomes in the FORZA trial</dc:title>
<dc:identifier>pmid:38848104</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae290</dc:identifier>
</item>
<item>
<title>The Artificial Intelligence Act approved by the EU: the difficult dialogue between the black box and the cardiologist</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38848102/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240607180913&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 7:ehae281. doi: 10.1093/eurheartj/ehae281. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38848102/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240607180913&v=2.18.0.post9+e462414">38848102</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae281>10.1093/eurheartj/ehae281</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38848102</guid>
<pubDate>Fri, 07 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Piotr Szymański</dc:creator>
<dc:creator>Frank Rademakers</dc:creator>
<dc:creator>Alan G Fraser</dc:creator>
<dc:date>2024-06-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>The Artificial Intelligence Act approved by the EU: the difficult dialogue between the black box and the cardiologist</dc:title>
<dc:identifier>pmid:38848102</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae281</dc:identifier>
</item>
<item>
<title>Weekly Journal Scan: Drug-coated balloon for the treatment of in-stent restenosis - the AGENT IDE trial</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38848101/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240607180913&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 7:ehae305. doi: 10.1093/eurheartj/ehae305. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38848101/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240607180913&v=2.18.0.post9+e462414">38848101</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae305>10.1093/eurheartj/ehae305</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38848101</guid>
<pubDate>Fri, 07 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Daniela Pedicino</dc:creator>
<dc:creator>Rocco Vergallo</dc:creator>
<dc:date>2024-06-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Weekly Journal Scan: Drug-coated balloon for the treatment of in-stent restenosis - the AGENT IDE trial</dc:title>
<dc:identifier>pmid:38848101</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae305</dc:identifier>
</item>
<item>
<title>Cancer begets atrial fibrillation … and vice versa?</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38848100/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240607180913&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 7:ehae301. doi: 10.1093/eurheartj/ehae301. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38848100/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240607180913&v=2.18.0.post9+e462414">38848100</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae301>10.1093/eurheartj/ehae301</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38848100</guid>
<pubDate>Fri, 07 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Dimitrios Farmakis</dc:creator>
<dc:creator>Gerasimos Filippatos</dc:creator>
<dc:date>2024-06-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Cancer begets atrial fibrillation … and vice versa?</dc:title>
<dc:identifier>pmid:38848100</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae301</dc:identifier>
</item>
<item>
<title>Office measurement vs. ambulatory blood pressure monitoring: associations with mortality in patients with or without diabetes</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38847237/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240607180913&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Diabetes increased the risk for all-cause death, CV, and non-CV death at every level of office and ambulatory BP. Masked and sustained hypertension confer to the highest risk, while white-coat hypertension appears grossly neutral without interaction of relative risk between diabetes and no diabetes. These results support recommendations of international guidelines for strict BP control and using ABPM for classification and assessment of risk and control of hypertension, particularly...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 7:ehae337. doi: 10.1093/eurheartj/ehae337. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND AND AIMS: Guidelines suggest similar blood pressure (BP) targets in patients with and without diabetes and recommend ambulatory BP monitoring (ABPM) to diagnose and classify hypertension. It was explored whether different levels of ambulatory and office BP and different hypertension phenotypes associate with differences of risk in diabetes and no diabetes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: This analysis assessed outcome data from the Spanish ABPM Registry in 59 124 patients with complete available data. The associations between office, mean, daytime, and nighttime ambulatory BP with the risk in patients with or without diabetes were explored. The effects of diabetes on mortality in different hypertension phenotypes, i.e. sustained hypertension, white-coat hypertension, and masked hypertension, compared with normotension were studied. Analyses were done with Cox regression analyses and adjusted for demographic and clinical confounders.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: A total of 59 124 patients were recruited from 223 primary care centres in Spain. The majority had an office systolic BP >;140 mmHg (36 700 patients), and 23 128 (40.6%) patients were untreated. Diabetes was diagnosed in 11 391 patients (19.2%). Concomitant cardiovascular (CV) disease was present in 2521 patients (23.1%) with diabetes and 4616 (10.0%) without diabetes. Twenty-four-hour mean, daytime, and nighttime ambulatory BP were associated with increased risk in diabetes and no diabetes, while in office BP, there was no clear association with no differences with and without diabetes. While the relative association of BP to CV death risk was similar in diabetes compared with no diabetes (mean interaction P = .80, daytime interaction P = .97, and nighttime interaction P = .32), increased event rates occurred in diabetes for all ABPM parameters for CV death and all-cause death. White-coat hypertension was not associated with risk for CV death (hazard ratio 0.86; 95% confidence interval 0.72-1.03) and slightly reduced risk for all-cause death in no diabetes (hazard ratio 0.89; confidence interval 0.81-0.98) but without significant interaction between diabetes and no diabetes. Sustained hypertension and masked hypertension in diabetes and no diabetes were associated with even higher risk. There were no significant interactions in hypertensive phenotypes between diabetes and no diabetes and CV death risk (interaction P = .26), while some interaction was present for all-cause death (interaction P = .043) and non-CV death (interaction P = .053).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Diabetes increased the risk for all-cause death, CV, and non-CV death at every level of office and ambulatory BP. Masked and sustained hypertension confer to the highest risk, while white-coat hypertension appears grossly neutral without interaction of relative risk between diabetes and no diabetes. These results support recommendations of international guidelines for strict BP control and using ABPM for classification and assessment of risk and control of hypertension, particularly in patients with diabetes.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CLINICAL TRIAL REGISTRATION: Not applicable.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38847237/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240607180913&v=2.18.0.post9+e462414">38847237</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae337>10.1093/eurheartj/ehae337</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38847237</guid>
<pubDate>Fri, 07 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Michael Böhm</dc:creator>
<dc:creator>Alejandro de la Sierra</dc:creator>
<dc:creator>Felix Mahfoud</dc:creator>
<dc:creator>Igor Schwantke</dc:creator>
<dc:creator>Lucas Lauder</dc:creator>
<dc:creator>Bernhard Haring</dc:creator>
<dc:creator>Ernest Vinyoles</dc:creator>
<dc:creator>Manuel Gorostidi</dc:creator>
<dc:creator>Julián Segura</dc:creator>
<dc:creator>Bryan Williams</dc:creator>
<dc:creator>Natalie Staplin</dc:creator>
<dc:creator>Luis M Ruilope</dc:creator>
<dc:date>2024-06-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Office measurement vs. ambulatory blood pressure monitoring: associations with mortality in patients with or without diabetes</dc:title>
<dc:identifier>pmid:38847237</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae337</dc:identifier>
</item>
<item>
<title>Tipifarnib Reduces Extracellular Vesicles and Protects From Heart Failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38847080/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240607180913&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: Our study underscores the pathological role of exosomes in HF and fibrosis in response to pressure overload. Tipifarnib-mediated inhibition of exosome biogenesis and cargo sorting may serve as a viable strategy to prevent progressive cardiac remodeling in HF.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jun 7. doi: 10.1161/CIRCRESAHA.123.324110. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND: Heart failure (HF) is one of the leading causes of mortality worldwide. Extracellular vesicles, including small extracellular vesicles or exosomes, and their molecular cargo are known to modulate cell-to-cell communication during multiple cardiac diseases. However, the role of systemic extracellular vesicle biogenesis inhibition in HF models is not well documented and remains unclear.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: We investigated the role of circulating exosomes during cardiac dysfunction and remodeling in a mouse transverse aortic constriction (TAC) model of HF. Importantly, we investigate the efficacy of tipifarnib, a recently identified exosome biogenesis inhibitor that targets the critical proteins (Rab27a, nSMase2 [neutral sphingomyelinase 2], and Alix [ALG-2-interacting protein X]) involved in exosome biogenesis for this mouse model of HF. In this study, 10-week-old male mice underwent TAC surgery were randomly assigned to groups with and without tipifarnib treatment (10 mg/kg 3 times/wk) and monitored for 8 weeks, and a comprehensive assessment was conducted through performed echocardiographic, histological, and biochemical studies.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: TAC significantly elevated circulating plasma exosomes and markedly increased cardiac left ventricular dysfunction, cardiac hypertrophy, and fibrosis. Furthermore, injection of plasma exosomes from TAC mice induced left ventricular dysfunction and cardiomyocyte hypertrophy in uninjured mice without TAC. On the contrary, treatment of tipifarnib in TAC mice reduced circulating exosomes to baseline and remarkably improved left ventricular functions, hypertrophy, and fibrosis. Tipifarnib treatment also drastically altered the miRNA profile of circulating post-TAC exosomes, including miR 331-5p, which was highly downregulated both in TAC circulating exosomes and in TAC cardiac tissue. Mechanistically, miR 331-5p is crucial for inhibiting the fibroblast-to-myofibroblast transition by targeting HOXC8, a critical regulator of fibrosis. Tipifarnib treatment in TAC mice upregulated the expression of miR 331-5p that acts as a potent repressor for one of the fibrotic mechanisms mediated by HOXC8.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: Our study underscores the pathological role of exosomes in HF and fibrosis in response to pressure overload. Tipifarnib-mediated inhibition of exosome biogenesis and cargo sorting may serve as a viable strategy to prevent progressive cardiac remodeling in HF.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38847080/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240607180913&v=2.18.0.post9+e462414">38847080</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.123.324110>10.1161/CIRCRESAHA.123.324110</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38847080</guid>
<pubDate>Fri, 07 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Vandana Mallaredy</dc:creator>
<dc:creator>Rajika Roy</dc:creator>
<dc:creator>Zhongjian Cheng</dc:creator>
<dc:creator>Charan Thej Gurrala</dc:creator>
<dc:creator>Cindy Benedict</dc:creator>
<dc:creator>May Truongcao</dc:creator>
<dc:creator>Darukeshwara Joladarashi</dc:creator>
<dc:creator>Ajit Magadum</dc:creator>
<dc:creator>Jessica Ibetti</dc:creator>
<dc:creator>Maria Cimini</dc:creator>
<dc:creator>Carolina Gonzalez</dc:creator>
<dc:creator>Venkata Naga Srikanth Garikipati</dc:creator>
<dc:creator>Walter J Koch</dc:creator>
<dc:creator>Raj Kishore</dc:creator>
<dc:date>2024-06-07</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Tipifarnib Reduces Extracellular Vesicles and Protects From Heart Failure</dc:title>
<dc:identifier>pmid:38847080</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.123.324110</dc:identifier>
</item>
<item>
<title>Loop diuretic utilisation with or without heart failure: impact on prognosis</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38845446/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240607180913&amp;v=2.18.0.post9+e462414
      <description>CONCLUSIONS: For patients with cardiovascular disease, many are prescribed loop diuretics without a diagnosis of heart failure being recorded. Mortality is more strongly associated with loop diuretic use than with a heart failure record. The diagnosis of heart failure may be often missed, or loop diuretic use is associated with other conditions with a prognosis similar to heart failure, or inappropriate loop diuretic use increases mortality; all might be true.</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 7:ehae345. doi: 10.1093/eurheartj/ehae345. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">BACKGROUND & AIMS: Many patients are prescribed loop diuretics without a diagnostic record of heart failure. Little is known about their characteristics and prognosis.</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">METHODS: Glasgow regional health records (2009-2016) were obtained for adults with cardiovascular disease or taking loop diuretics. Outcomes were investigated using Cox models with hazard ratios adjusted for age, sex, socioeconomic deprivation, and co-morbid disease (adjHR).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">RESULTS: Of 198,898 patients (median age 65 years; 55% women), 161,935 (81%) neither took loop diuretics nor had a diagnostic record of heart failure (reference group), 23,963 (12%) were taking loop diuretics but had no heart failure recorded, 7,844 (4%) had heart failure recorded and took loop diuretics and 5,156 (3%) had heart failure recorded but were not receiving loop diuretics.Five-year mortality was only slightly higher for heart failure in absence of loop diuretics (22%; adjHR: 1.2 [95% CI 1.1-1.3]), substantially higher for those taking loop diuretics with no heart failure recorded (40%; adjHR: 1.8 [95% CI 1.7-1.8]) and highest for heart failure treated with loop diuretics (52%; adjHR: 2.2 [95% CI 2.0-2.2]).</p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">CONCLUSIONS: For patients with cardiovascular disease, many are prescribed loop diuretics without a diagnosis of heart failure being recorded. Mortality is more strongly associated with loop diuretic use than with a heart failure record. The diagnosis of heart failure may be often missed, or loop diuretic use is associated with other conditions with a prognosis similar to heart failure, or inappropriate loop diuretic use increases mortality; all might be true.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38845446/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240607180913&v=2.18.0.post9+e462414">38845446</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae345>10.1093/eurheartj/ehae345</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38845446</guid>
<pubDate>Fri, 07 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Jocelyn M Friday</dc:creator>
<dc:creator>John Gf Cleland</dc:creator>
<dc:creator>Pierpaolo Pellicori</dc:creator>
<dc:creator>Maria Wolters</dc:creator>
<dc:creator>John Jv McMurray</dc:creator>
<dc:creator>Pardeep S Jhund</dc:creator>
<dc:creator>Paul Forsyth</dc:creator>
<dc:creator>David A McAllister</dc:creator>
<dc:creator>Fraser J Graham</dc:creator>
<dc:creator>Yola Jones</dc:creator>
<dc:creator>Jim Lewsey</dc:creator>
<dc:date>2024-06-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Loop diuretic utilisation with or without heart failure: impact on prognosis</dc:title>
<dc:identifier>pmid:38845446</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae345</dc:identifier>
</item>
<item>
<title>Education in cardio-oncology: the next frontiers</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38845152/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240607180913&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 7:ehad895. doi: 10.1093/eurheartj/ehad895. Online ahead of print.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38845152/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240607180913&v=2.18.0.post9+e462414">38845152</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehad895>10.1093/eurheartj/ehad895</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38845152</guid>
<pubDate>Fri, 07 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Dimitrios Farmakis</dc:creator>
<dc:creator>Joerg Hermann</dc:creator>
<dc:creator>Alexander R Lyon</dc:creator>
<dc:creator>Teresa López-Fernández</dc:creator>
<dc:date>2024-06-07</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Education in cardio-oncology: the next frontiers</dc:title>
<dc:identifier>pmid:38845152</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehad895</dc:identifier>
</item>
<item>
<title>Focus on emerging cancer drugs, artificial intelligence applied to imaging, and a new therapeutic target in heart failure</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38843882/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240607180913&amp;v=2.18.0.post9+e462414
      <description>No abstract</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Eur Heart J. 2024 Jun 7;45(22):1959-1962. doi: 10.1093/eurheartj/ehae353.</p><p><b>NO ABSTRACT</b></p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38843882/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240607180913&v=2.18.0.post9+e462414">38843882</a> | DOI:<a href=https://doi.org/10.1093/eurheartj/ehae353>10.1093/eurheartj/ehae353</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38843882</guid>
<pubDate>Thu, 06 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Filippo Crea</dc:creator>
<dc:date>2024-06-06</dc:date>
<dc:source>European heart journal</dc:source>
<dc:title>Focus on emerging cancer drugs, artificial intelligence applied to imaging, and a new therapeutic target in heart failure</dc:title>
<dc:identifier>pmid:38843882</dc:identifier>
<dc:identifier>doi:10.1093/eurheartj/ehae353</dc:identifier>
</item>
<item>
<title>Discovery of antimicrobial peptides in the global microbiome with machine learning</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38843834/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240607180913&amp;v=2.18.0.post9+e462414
      <description>Novel antibiotics are urgently needed to combat the antibiotic-resistance crisis. We present a machine-learning-based approach to predict antimicrobial peptides (AMPs) within the global microbiome and leverage a vast dataset of 63,410 metagenomes and 87,920 prokaryotic genomes from environmental and host-associated habitats to create the AMPSphere, a comprehensive catalog comprising 863,498 non-redundant peptides, few of which match existing databases. AMPSphere provides insights into the...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 May 30:S0092-8674(24)00522-1. doi: 10.1016/j.cell.2024.05.013. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Novel antibiotics are urgently needed to combat the antibiotic-resistance crisis. We present a machine-learning-based approach to predict antimicrobial peptides (AMPs) within the global microbiome and leverage a vast dataset of 63,410 metagenomes and 87,920 prokaryotic genomes from environmental and host-associated habitats to create the AMPSphere, a comprehensive catalog comprising 863,498 non-redundant peptides, few of which match existing databases. AMPSphere provides insights into the evolutionary origins of peptides, including by duplication or gene truncation of longer sequences, and we observed that AMP production varies by habitat. To validate our predictions, we synthesized and tested 100 AMPs against clinically relevant drug-resistant pathogens and human gut commensals both in vitro and in vivo. A total of 79 peptides were active, with 63 targeting pathogens. These active AMPs exhibited antibacterial activity by disrupting bacterial membranes. In conclusion, our approach identified nearly one million prokaryotic AMP sequences, an open-access resource for antibiotic discovery.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38843834/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240607180913&v=2.18.0.post9+e462414">38843834</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.05.013>10.1016/j.cell.2024.05.013</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38843834</guid>
<pubDate>Thu, 06 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Célio Dias Santos-Júnior</dc:creator>
<dc:creator>Marcelo D T Torres</dc:creator>
<dc:creator>Yiqian Duan</dc:creator>
<dc:creator>Álvaro Rodríguez Del Río</dc:creator>
<dc:creator>Thomas S B Schmidt</dc:creator>
<dc:creator>Hui Chong</dc:creator>
<dc:creator>Anthony Fullam</dc:creator>
<dc:creator>Michael Kuhn</dc:creator>
<dc:creator>Chengkai Zhu</dc:creator>
<dc:creator>Amy Houseman</dc:creator>
<dc:creator>Jelena Somborski</dc:creator>
<dc:creator>Anna Vines</dc:creator>
<dc:creator>Xing-Ming Zhao</dc:creator>
<dc:creator>Peer Bork</dc:creator>
<dc:creator>Jaime Huerta-Cepas</dc:creator>
<dc:creator>Cesar de la Fuente-Nunez</dc:creator>
<dc:creator>Luis Pedro Coelho</dc:creator>
<dc:date>2024-06-06</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Discovery of antimicrobial peptides in the global microbiome with machine learning</dc:title>
<dc:identifier>pmid:38843834</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.05.013</dc:identifier>
</item>
<item>
<title>The ribotoxic stress response drives UV-mediated cell death</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38843833/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240607180913&amp;v=2.18.0.post9+e462414
      <description>While ultraviolet (UV) radiation damages DNA, eliciting the DNA damage response (DDR), it also damages RNA, triggering transcriptome-wide ribosomal collisions and eliciting a ribotoxic stress response (RSR). However, the relative contributions, timing, and regulation of these pathways in determining cell fate is unclear. Here we use time-resolved phosphoproteomic, chemical-genetic, single-cell imaging, and biochemical approaches to create a chronological atlas of signaling events activated in...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 May 31:S0092-8674(24)00527-0. doi: 10.1016/j.cell.2024.05.018. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">While ultraviolet (UV) radiation damages DNA, eliciting the DNA damage response (DDR), it also damages RNA, triggering transcriptome-wide ribosomal collisions and eliciting a ribotoxic stress response (RSR). However, the relative contributions, timing, and regulation of these pathways in determining cell fate is unclear. Here we use time-resolved phosphoproteomic, chemical-genetic, single-cell imaging, and biochemical approaches to create a chronological atlas of signaling events activated in cells responding to UV damage. We discover that UV-induced apoptosis is mediated by the RSR kinase ZAK and not through the DDR. We identify two negative-feedback modules that regulate ZAK-mediated apoptosis: (1) GCN2 activation limits ribosomal collisions and attenuates ZAK-mediated RSR and (2) ZAK activity leads to phosphodegron autophosphorylation and its subsequent degradation. These events tune ZAK's activity to collision levels to establish regimes of homeostasis, tolerance, and death, revealing its key role as the cellular sentinel for nucleic acid damage.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38843833/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240607180913&v=2.18.0.post9+e462414">38843833</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.05.018>10.1016/j.cell.2024.05.018</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38843833</guid>
<pubDate>Thu, 06 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Niladri K Sinha</dc:creator>
<dc:creator>Connor McKenney</dc:creator>
<dc:creator>Zhong Y Yeow</dc:creator>
<dc:creator>Jeffrey J Li</dc:creator>
<dc:creator>Ki Hong Nam</dc:creator>
<dc:creator>Tomer M Yaron-Barir</dc:creator>
<dc:creator>Jared L Johnson</dc:creator>
<dc:creator>Emily M Huntsman</dc:creator>
<dc:creator>Lewis C Cantley</dc:creator>
<dc:creator>Alban Ordureau</dc:creator>
<dc:creator>Sergi Regot</dc:creator>
<dc:creator>Rachel Green</dc:creator>
<dc:date>2024-06-06</dc:date>
<dc:source>Cell</dc:source>
<dc:title>The ribotoxic stress response drives UV-mediated cell death</dc:title>
<dc:identifier>pmid:38843833</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.05.018</dc:identifier>
</item>
<item>
<title>Capturing totipotency in human cells through spliceosomal repression</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38843832/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240607180913&amp;v=2.18.0.post9+e462414
      <description>The cleavage of zygotes generates totipotent blastomeres. In human 8-cell blastomeres, zygotic genome activation (ZGA) occurs to initiate the ontogenesis program. However, capturing and maintaining totipotency in human cells pose significant challenges. Here, we realize culturing human totipotent blastomere-like cells (hTBLCs). We find that splicing inhibition can transiently reprogram human pluripotent stem cells into ZGA-like cells (ZLCs), which subsequently transition into stable hTBLCs after...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 Jun 3:S0092-8674(24)00519-1. doi: 10.1016/j.cell.2024.05.010. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The cleavage of zygotes generates totipotent blastomeres. In human 8-cell blastomeres, zygotic genome activation (ZGA) occurs to initiate the ontogenesis program. However, capturing and maintaining totipotency in human cells pose significant challenges. Here, we realize culturing human totipotent blastomere-like cells (hTBLCs). We find that splicing inhibition can transiently reprogram human pluripotent stem cells into ZGA-like cells (ZLCs), which subsequently transition into stable hTBLCs after long-term passaging. Distinct from reported 8-cell-like cells (8CLCs), both ZLCs and hTBLCs widely silence pluripotent genes. Interestingly, ZLCs activate a particular group of ZGA-specific genes, and hTBLCs are enriched with pre-ZGA-specific genes. During spontaneous differentiation, hTBLCs re-enter the intermediate ZLC stage and further generate epiblast (EPI)-, primitive endoderm (PrE)-, and trophectoderm (TE)-like lineages, effectively recapitulating human pre-implantation development. Possessing both embryonic and extraembryonic developmental potency, hTBLCs can autonomously generate blastocyst-like structures in vitro without external cell signaling. In summary, our study provides key criteria and insights into human cell totipotency.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38843832/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240607180913&v=2.18.0.post9+e462414">38843832</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.05.010>10.1016/j.cell.2024.05.010</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38843832</guid>
<pubDate>Thu, 06 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Shiyu Li</dc:creator>
<dc:creator>Min Yang</dc:creator>
<dc:creator>Hui Shen</dc:creator>
<dc:creator>Li Ding</dc:creator>
<dc:creator>Xuehui Lyu</dc:creator>
<dc:creator>Kexin Lin</dc:creator>
<dc:creator>Jennie Ong</dc:creator>
<dc:creator>Peng Du</dc:creator>
<dc:date>2024-06-06</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Capturing totipotency in human cells through spliceosomal repression</dc:title>
<dc:identifier>pmid:38843832</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.05.010</dc:identifier>
</item>
<item>
<title>Heterologous survey of 130 DNA transposons in human cells highlights their functional divergence and expands the genome engineering toolbox</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38843831/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240607180913&amp;v=2.18.0.post9+e462414
      <description>Experimental studies on DNA transposable elements (TEs) have been limited in scale, leading to a lack of understanding of the factors influencing transposition activity, evolutionary dynamics, and application potential as genome engineering tools. We predicted 130 active DNA TEs from 102 metazoan genomes and evaluated their activity in human cells. We identified 40 active (integration-competent) TEs, surpassing the cumulative number (20) of TEs found previously. With this unified comparative...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;"><b>Cell</b>. 2024 May 29:S0092-8674(24)00516-6. doi: 10.1016/j.cell.2024.05.007. Online ahead of print.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Experimental studies on DNA transposable elements (TEs) have been limited in scale, leading to a lack of understanding of the factors influencing transposition activity, evolutionary dynamics, and application potential as genome engineering tools. We predicted 130 active DNA TEs from 102 metazoan genomes and evaluated their activity in human cells. We identified 40 active (integration-competent) TEs, surpassing the cumulative number (20) of TEs found previously. With this unified comparative data, we found that the Tc1/mariner superfamily exhibits elevated activity, potentially explaining their pervasive horizontal transfers. Further functional characterization of TEs revealed additional divergence in features such as insertion bias. Remarkably, in CAR-T therapy for hematological and solid tumors, Mariner2_AG (MAG), the most active DNA TE identified, largely outperformed two widely used vectors, the lentiviral vector and the TE-based vector SB100X. Overall, this study highlights the varied transposition features and evolutionary dynamics of DNA TEs and increases the TE toolbox diversity.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38843831/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240607180913&v=2.18.0.post9+e462414">38843831</a> | DOI:<a href=https://doi.org/10.1016/j.cell.2024.05.007>10.1016/j.cell.2024.05.007</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38843831</guid>
<pubDate>Thu, 06 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Tongtong Zhang</dc:creator>
<dc:creator>Shengjun Tan</dc:creator>
<dc:creator>Na Tang</dc:creator>
<dc:creator>Yuanqing Li</dc:creator>
<dc:creator>Chenze Zhang</dc:creator>
<dc:creator>Jing Sun</dc:creator>
<dc:creator>Yanyan Guo</dc:creator>
<dc:creator>Hui Gao</dc:creator>
<dc:creator>Yujia Cai</dc:creator>
<dc:creator>Wen Sun</dc:creator>
<dc:creator>Chenxin Wang</dc:creator>
<dc:creator>Liangzheng Fu</dc:creator>
<dc:creator>Huijing Ma</dc:creator>
<dc:creator>Yachao Wu</dc:creator>
<dc:creator>Xiaoxuan Hu</dc:creator>
<dc:creator>Xuechun Zhang</dc:creator>
<dc:creator>Peter Gee</dc:creator>
<dc:creator>Weihua Yan</dc:creator>
<dc:creator>Yahui Zhao</dc:creator>
<dc:creator>Qiang Chen</dc:creator>
<dc:creator>Baocheng Guo</dc:creator>
<dc:creator>Haoyi Wang</dc:creator>
<dc:creator>Yong E Zhang</dc:creator>
<dc:date>2024-06-06</dc:date>
<dc:source>Cell</dc:source>
<dc:title>Heterologous survey of 130 DNA transposons in human cells highlights their functional divergence and expands the genome engineering toolbox</dc:title>
<dc:identifier>pmid:38843831</dc:identifier>
<dc:identifier>doi:10.1016/j.cell.2024.05.007</dc:identifier>
</item>
<item>
<title>Myocardial Inflammation in Heart Failure With Reduced and Preserved Ejection Fraction</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38843295/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240607180913&amp;v=2.18.0.post9+e462414
      <description>Heart failure (HF) is characterized by a progressive decline in cardiac function and represents one of the largest health burdens worldwide. Clinically, 2 major types of HF are distinguished based on the left ventricular ejection fraction (EF): HF with reduced EF and HF with preserved EF. While both types share several risk factors and features of adverse cardiac remodeling, unique hallmarks beyond ejection fraction that distinguish these etiologies also exist. These differences may explain the...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jun 7;134(12):1752-1766. doi: 10.1161/CIRCRESAHA.124.323659. Epub 2024 Jun 6.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Heart failure (HF) is characterized by a progressive decline in cardiac function and represents one of the largest health burdens worldwide. Clinically, 2 major types of HF are distinguished based on the left ventricular ejection fraction (EF): HF with reduced EF and HF with preserved EF. While both types share several risk factors and features of adverse cardiac remodeling, unique hallmarks beyond ejection fraction that distinguish these etiologies also exist. These differences may explain the fact that approved therapies for HF with reduced EF are largely ineffective in patients suffering from HF with preserved EF. Improving our understanding of the distinct cellular and molecular mechanisms is crucial for the development of better treatment strategies. This article reviews the knowledge of the immunologic mechanisms underlying HF with reduced and preserved EF and discusses how the different immune profiles elicited may identify attractive therapeutic targets for these conditions. We review the literature on the reported mechanisms of adverse cardiac remodeling in HF with reduced and preserved EF, as well as the immune mechanisms involved. We discuss how the knowledge gained from preclinical models of the complex syndrome of HF as well as from clinical data obtained from patients may translate to a better understanding of HF and result in specific treatments for these conditions in humans.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38843295/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240607180913&v=2.18.0.post9+e462414">38843295</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.323659>10.1161/CIRCRESAHA.124.323659</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38843295</guid>
<pubDate>Thu, 06 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Pilar Alcaide</dc:creator>
<dc:creator>Marinos Kallikourdis</dc:creator>
<dc:creator>Ramona Emig</dc:creator>
<dc:creator>Sumanth D Prabhu</dc:creator>
<dc:date>2024-06-06</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Myocardial Inflammation in Heart Failure With Reduced and Preserved Ejection Fraction</dc:title>
<dc:identifier>pmid:38843295</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.323659</dc:identifier>
</item>
<item>
<title>Repair of the Infarcted Heart: Cellular Effectors, Molecular Mechanisms and Therapeutic Opportunities</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38843294/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240607180913&amp;v=2.18.0.post9+e462414
      <description>The adult mammalian heart has limited endogenous regenerative capacity and heals through the activation of inflammatory and fibrogenic cascades that ultimately result in the formation of a scar. After infarction, massive cardiomyocyte death releases a broad range of damage-associated molecular patterns that initiate both myocardial and systemic inflammatory responses. TLRs (toll-like receptors) and NLRs (NOD-like receptors) recognize damage-associated molecular patterns (DAMPs) and transduce...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jun 7;134(12):1718-1751. doi: 10.1161/CIRCRESAHA.124.323658. Epub 2024 Jun 6.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">The adult mammalian heart has limited endogenous regenerative capacity and heals through the activation of inflammatory and fibrogenic cascades that ultimately result in the formation of a scar. After infarction, massive cardiomyocyte death releases a broad range of damage-associated molecular patterns that initiate both myocardial and systemic inflammatory responses. TLRs (toll-like receptors) and NLRs (NOD-like receptors) recognize damage-associated molecular patterns (DAMPs) and transduce downstream proinflammatory signals, leading to upregulation of cytokines (such as interleukin-1, TNF-α [tumor necrosis factor-α], and interleukin-6) and chemokines (such as CCL2 [CC chemokine ligand 2]) and recruitment of neutrophils, monocytes, and lymphocytes. Expansion and diversification of cardiac macrophages in the infarcted heart play a major role in the clearance of the infarct from dead cells and the subsequent stimulation of reparative pathways. Efferocytosis triggers the induction and release of anti-inflammatory mediators that restrain the inflammatory reaction and set the stage for the activation of reparative fibroblasts and vascular cells. Growth factor-mediated pathways, neurohumoral cascades, and matricellular proteins deposited in the provisional matrix stimulate fibroblast activation and proliferation and myofibroblast conversion. Deposition of a well-organized collagen-based extracellular matrix network protects the heart from catastrophic rupture and attenuates ventricular dilation. Scar maturation requires stimulation of endogenous signals that inhibit fibroblast activity and prevent excessive fibrosis. Moreover, in the mature scar, infarct neovessels acquire a mural cell coat that contributes to the stabilization of the microvascular network. Excessive, prolonged, or dysregulated inflammatory or fibrogenic cascades accentuate adverse remodeling and dysfunction. Moreover, inflammatory leukocytes and fibroblasts can contribute to arrhythmogenesis. Inflammatory and fibrogenic pathways may be promising therapeutic targets to attenuate heart failure progression and inhibit arrhythmia generation in patients surviving myocardial infarction.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38843294/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240607180913&v=2.18.0.post9+e462414">38843294</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.323658>10.1161/CIRCRESAHA.124.323658</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38843294</guid>
<pubDate>Thu, 06 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Ingo Hilgendorf</dc:creator>
<dc:creator>Stefan Frantz</dc:creator>
<dc:creator>Nikolaos G Frangogiannis</dc:creator>
<dc:date>2024-06-06</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Repair of the Infarcted Heart: Cellular Effectors, Molecular Mechanisms and Therapeutic Opportunities</dc:title>
<dc:identifier>pmid:38843294</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.323658</dc:identifier>
</item>
<item>
<title>Dissecting and Visualizing the Functional Diversity of Cardiac Macrophages</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38843293/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240607180913&amp;v=2.18.0.post9+e462414
      <description>Cardiac macrophages represent a functionally diverse population of cells involved in cardiac homeostasis, repair, and remodeling. With recent advancements in single-cell technologies, it is possible to elucidate specific macrophage subsets based on transcriptional signatures and cell surface protein expression to gain a deep understanding of macrophage diversity in the heart. The use of fate-mapping technologies and parabiosis studies have provided insight into the ontogeny and dynamics of...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jun 7;134(12):1791-1807. doi: 10.1161/CIRCRESAHA.124.323817. Epub 2024 Jun 6.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Cardiac macrophages represent a functionally diverse population of cells involved in cardiac homeostasis, repair, and remodeling. With recent advancements in single-cell technologies, it is possible to elucidate specific macrophage subsets based on transcriptional signatures and cell surface protein expression to gain a deep understanding of macrophage diversity in the heart. The use of fate-mapping technologies and parabiosis studies have provided insight into the ontogeny and dynamics of macrophages identifying subsets derived from embryonic and adult definitive hematopoietic progenitors that include tissue-resident and bone marrow monocyte-derived macrophages, respectively. Within the heart, these subsets have distinct tissue niches and functional roles in the setting of homeostasis and disease, with cardiac resident macrophages representing a protective cell population while bone marrow monocyte-derived cardiac macrophages have a context-dependent effect, triggering both proinflammatory tissue injury, but also promoting reparative functions. With the increased understanding of the clinical relevance of cardiac macrophage subsets, there has been an increasing need to detect and measure cardiac macrophage compositions in living animals and patients. New molecular tracers compatible with positron emission tomography/computerized tomography and positron emission tomography/ magnetic resonance imaging have enabled investigators to noninvasively and serially visualize cardiac macrophage subsets within the heart to define associations with disease and measure treatment responses. Today, advancements within this thriving field are poised to fuel an era of clinical translation.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38843293/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240607180913&v=2.18.0.post9+e462414">38843293</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.323817>10.1161/CIRCRESAHA.124.323817</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38843293</guid>
<pubDate>Thu, 06 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Megan Holt</dc:creator>
<dc:creator>Julia Lin</dc:creator>
<dc:creator>Markus Cicka</dc:creator>
<dc:creator>Anthony Wong</dc:creator>
<dc:creator>Slava Epelman</dc:creator>
<dc:creator>Kory J Lavine</dc:creator>
<dc:date>2024-06-06</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Dissecting and Visualizing the Functional Diversity of Cardiac Macrophages</dc:title>
<dc:identifier>pmid:38843293</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.323817</dc:identifier>
</item>
<item>
<title>Autoimmune Myocarditis, Old Dogs and New Tricks</title>
<link/>https://pubmed.ncbi.nlm.nih.gov/38843292/?utm_source=Chrome&amp;utm_medium=rss&amp;utm_campaign=pubmed-2&amp;utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&amp;fc=20230708114047&amp;ff=20240607180913&amp;v=2.18.0.post9+e462414
      <description>Autoimmunity significantly contributes to the pathogenesis of myocarditis, underscored by its increased frequency in autoimmune diseases such as systemic lupus erythematosus and polymyositis. Even in cases of myocarditis caused by viral infections, dysregulated immune responses contribute to pathogenesis. However, whether triggered by existing autoimmune conditions or viral infections, the precise antigens and immunologic pathways driving myocarditis remain incompletely understood. The emergence...</description>
<content:encoded><![CDATA[<div><p style="color: #4aa564;">Circ Res. 2024 Jun 7;134(12):1767-1790. doi: 10.1161/CIRCRESAHA.124.323816. Epub 2024 Jun 6.</p><p><b>ABSTRACT</b></p><p xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:p1="http://pubmed.gov/pub-one">Autoimmunity significantly contributes to the pathogenesis of myocarditis, underscored by its increased frequency in autoimmune diseases such as systemic lupus erythematosus and polymyositis. Even in cases of myocarditis caused by viral infections, dysregulated immune responses contribute to pathogenesis. However, whether triggered by existing autoimmune conditions or viral infections, the precise antigens and immunologic pathways driving myocarditis remain incompletely understood. The emergence of myocarditis associated with immune checkpoint inhibitor therapy, commonly used for treating cancer, has afforded an opportunity to understand autoimmune mechanisms in myocarditis, with autoreactive T cells specific for cardiac myosin playing a pivotal role. Despite their self-antigen recognition, cardiac myosin-specific T cells can be present in healthy individuals due to bypassing the thymic selection stage. In recent studies, novel modalities in suppressing the activity of pathogenic T cells including cardiac myosin-specific T cells have proven effective in treating autoimmune myocarditis. This review offers an overview of the current understanding of heart antigens, autoantibodies, and immune cells as the autoimmune mechanisms underlying various forms of myocarditis, along with the latest updates on clinical management and prospects for future research.</p><p style="color: lightgray">PMID:<a href="https://pubmed.ncbi.nlm.nih.gov/38843292/?utm_source=Chrome&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1vUePJ4Z_tESAAXKwJxBoGOTaabXd6U-NVu8003KrCpq8yLQC-&fc=20230708114047&ff=20240607180913&v=2.18.0.post9+e462414">38843292</a> | DOI:<a href=https://doi.org/10.1161/CIRCRESAHA.124.323816>10.1161/CIRCRESAHA.124.323816</a></p></div>]]></content:encoded>
<guid ispermalink="false">pubmed:38843292</guid>
<pubDate>Thu, 06 Jun 2024 06:00:00 -0400</pubDate>
<dc:creator>Taejoon Won</dc:creator>
<dc:creator>Evelyn J Song</dc:creator>
<dc:creator>Hannah M Kalinoski</dc:creator>
<dc:creator>Javid J Moslehi</dc:creator>
<dc:creator>Daniela Čiháková</dc:creator>
<dc:date>2024-06-06</dc:date>
<dc:source>Circulation research</dc:source>
<dc:title>Autoimmune Myocarditis, Old Dogs and New Tricks</dc:title>
<dc:identifier>pmid:38843292</dc:identifier>
<dc:identifier>doi:10.1161/CIRCRESAHA.124.323816</dc:identifier>
</item>





























</channel>
</rss>